Search PubMed⌕ Search

Biomedical subjects

H Minaguchi

Publications and source records attributed to H Minaguchi.

At least 91 records · Page 5Linked to original sources
PubMed1992

[Prolactin disorders in patients with habitual abortion].

To evaluate the significance of prolactin (PRL) disorders as one of the etiologic factors in habitual abortion, one hundred and six couples with a history of recurrent spontaneous abortion were assessed clinically and endocrinologically. A high rate of PRL disorders (eight patients with hyperprolactinemia and 31 patients with occulted hyperprolactinemia) was observed (36.8%) in habitual aborters, and only nine of these patients showed clinically detectable luteal insufficiency. These patients who had PRL disorders without luteal insufficiency were further analyzed with immunological examinations. Immunological evaluations revealed that there was no significant difference between the subpopulations of peripheral blood lymphocytes (PBL) in patients with PRL disorders and normal controls while the PHA-stimulated blastogenic activity of PBL and ConA-induced IL-2 synthesis by PBL was slightly suppressed as compared with that of normal controls. And the incidence of HLA sharing in couples with PRL disorders was demonstrated to be higher than that of the normal control couples without abortion. Patients with PRL disorders without impaired corpus luteum function were treated with bromocriptine only, and this therapy was very effective in maintaining pregnancy. The results of this study have allowed us to suggest that PRL disorders might be some of the etiologies in the so called "unexplained" habitual abortion.

Abortion, Habitual↗
PubMed1991

Treatment effects of GnRH agonist on the binding of estrogen and progesterone, and the histological findings of uterine leiomyomas.

The changes in the histology and steroid hormone binding capacity of the uterine leiomyomas treated with; GnRH agonists (GnRHa buserelin acetate in, 900 micrograms/day for 16 weeks) were investigated. The occurrence of hyaline degeneration in the myometrium was significantly higher in the GnRHa-treated group than in the control group, and the grade of hyaline degeneration was more advanced in the GnRHa group. After the GnRHa treatment, the Bmax of the estrogen receptor increased significantly in the leiomyomas and myometrium. The Bmax of progesterone receptors in the myometrium decreased significantly and the reduction rates of leiomyomas (% of the initial volumes) measured by MRI correlated (r = 0.775) with the Bmax of progesterone receptors. In summary, GnRHa caused hyaline degeneration of the uterine leiomyomas which were responsible for the shrinkage. The shrunk leiomyomas have the potential for regrowth in response to estrogen as they still have high concentrations of the estrogen receptors.

Adult↗
PubMed1991

[Clinical evaluation of fleroxacin in gynecological infections].

Fleroxacin (FLRX), a new quinolone oral antibacterial agent, was studied in the field of obstetrics and gynecology, and the following results were obtained. 1. Clinical efficacy was evaluated in 105 patients (intrauterine infection 38, adnexitis 28, extragenital organ infection 29, others 10), with an exclusion of 9 patients out of a total of 114 patients. FLRX was orally administered at 200 mg or 300 mg once daily. 2. Clinical efficacy rates were 37/38 (97.4%) in intrauterine infection, 26/28 (92.9%) in adnexitis, 29/29 (100%) in extragenital organ infection and 10/10 (100%) in others. 3. Efficacy rates classified by isolated organisms were 23/23 (100%) in single infections by Gram-positive organisms, 11/13 (84.6%) in those by Gram-negative organisms, 8/9 (88.9%) in those by anaerobic organisms and 15/19 (78.9%) in mixed infections. 4. Side effects were observed in 4 cases (3.5%); gastrointestinal disorder with diarrhea and diarrhea in 1 patient each and insomnia in 2 patients. In laboratory examination, eosinophilia and elevation of GOT and GPT were noted in 1 patient each (1.9%). Based on the above results, we consider that FLRX is a useful drug for the obstetrical and gynecological infections.

Administration, Oral↗
PubMed1990

[Recurrence of endometrial cancer and its pathological factors].

The number of patients with uterine endometrial cancer has increased in recent years in Japan. The studies on the prognostic factors of endometrial cancer, however, have not been made in detail as compared with those on the prognostic factors of cervical cancers. We have therefore investigated retrospectively the prognoses of 94 cases with endometrial cancer treated in our clinic from 1973 to 1984. Out of 31 cases (32.9%) with recurrence, 13 cases were at the Stage I and II, and the recurrence ratios were 11.4% for Stage Ia, 18.2% for Stage Ib and 31.3% for Stage II. The prognosis of endometrial carcinoma appears to depend on the endocervical involvement of the cancer. Five prognostic factors for Stage I and II endometrial cancers analyzed here are as follows; (1) histologic differentiation (grade), (2) size (diameter) of the primary tumor, (3) myometrial invasion, (4) vascular invasion, (5) lymphnode metastasis. (1) The recurrence ratio was 15.0% in the well differentiated (Grade 1) group, 25.0% in the moderately differentiated (Grade 2) group, 27.3% in the poorly differentiated (Grade 3) group, and 12.5% in adenoacanthoma. (2) The ratio of recurrence was 2.9% with less than 3 cm diameter, 24% with 3-6 cm diameter, and 30% with greater than 6 cm diameter in tumor size. (3) The ratio of recurrence was 2.9% with less than 1/3, 24% with 1/3-2/3, and 30% with greater than 2/3 myometrial invasion. (4) The ratio of recurrence was 43.8% with vascular invasion, and 5.6% without it. (5) The ratio of recurrence was 75% with lymphnode metastasis, and 8.8% without it.(ABSTRACT TRUNCATED AT 250 WORDS)

Female↗
PubMed1990

Effect of prolactin (PRL) on lipoprotein lipase (LPL) activity in the rat fetal liver.

In order to clarify the possible involvement of PRL in the regulation of lipid metabolism, the influence of PRL on the levels of LPL activity in rat fetal liver was investigated. Rat fetuses at 18th day of gestation in one uterine horn were injected with o-PRL while those in the opposite horn with saline. Forty-eight hr later, the livers were removed from the fetuses, homogenized, defatted, dried overnight, and further homogenized to the enzyme suspension. The measurement of LPL activity in these suspensions revealed that LPL activity in the fetal liver treated with o-PRL was significantly higher than that of control. LPL activities in the rat fetal liver gradually increased until the time of birth as the gestation proceeded. These results suggest that PRL may be one of the factors regulating fetal lipid metabolism.

Animals↗
PubMed1990

Epidermal growth factor stimulate cell proliferation and inhibits prolactin secretion of the human decidual cells in culture.

Epidermal growth factor (EGF) has been found to be mitogenic in a variety of tissues. We investigated the biological effect of EGF on early pregnant human decidua and the non-pregnant decidualized human endometrium in the primary cell culture. EGF had a stimulatory action on cell proliferation in the early pregnant decidual cells and an inhibitory effect on prolactin (PRL) secretion from the decidual cells. The addition of progesterone into culture medium suppressed cell proliferation of decidual cells, whereas it enhanced PRL secretion from decidua. The analysis of the specific receptor for EGF in the early pregnant decidua and non-pregnant decidualized endometrium revealed that both tissues had a single component EGF receptor with a dissociation constant of nM order. These results suggest that EGF may play a role in the growth and function of endometrial stromal cells.

Cell Division↗
PubMed1990

Regulation of LH beta subunit mRNA in immature female rats during GnRH agonist treatment.

In order to determine the changes in the expression of LH beta messenger ribonucleic acid (mRNA) during GnRH agonist (GnRHa) treatment (0.94 mg/28 days), the concentration of the mRNA of LH beta was assessed together with the serum LH concentration, pituitary LH content and LH response to GnRH at various times during long-acting GnRHa treatment in immature female rats. The serum LH concentration was increased at hour 1, gradually decreased starting at approximately hour 3 and had returned to the control level on day 28. Pituitary LH began to decrease at hour 3. The concentrations of LH beta mRNA were not significantly different from those in the control group from hour 1 to hour 18, but were lower from day 3 to day 28. Serum LH response to native GnRH (1 micrograms) began to be inhibited on day 7. These results indicate that the short term treatment with GnRHa stimulates the release of preformed LH rather than synthesis of LH beta mRNA and that the long term treatment inhibited the expression of LH beta mRNA in a time dependent manner.

Animals↗
PubMed1989

[Effects of massive administration of cepharanthin on chemotherapy-induced leukopenia].

The effects of Cepharanthine on chemotherapy-induced leukopenia was investigated in our university hospital. Thirty-four patients with gynecological malignant tumors were divided into two groups: One group (20 patients) was administered 50 mg of Cepharanthine intravenously every day during postoperative chemotherapy (CAP or FAMT therapy) period and the other (14 patients) was without administration during the same period. Out of 20 patients treated with Cepharanthine, 14 patients (70%) showed a slight decrease in the number of leukocytes (less than 20% decrease as compared to that before chemotherapy) five weeks after administration of anticancer drugs. Only two patients (14%) demonstrated a slight decrease of the number of leukocytes in the control group. No side effects were observed in the patients who were treated with Cepharanthine. These data suggest that the large dose of Cepharanthine contribute to the prevention of leukopenia in patients who are treated with a sufficient amount of anticancer drugs.

Adult↗
PubMed1987

[Clinical effect of cefuzonam and its distribution into tissues in the field of obstetrics and gynecology].

The distribution of the new cephem antibiotic, cefuzonam (CZON) into adnexa uteri and uterine tissues, and clinical efficacy on patients with obstetric and gynecologic infections were studied. The results obtained are summarized as follows. 1. Concentrations of CZON in arterial and venous blood, oviduct, ovary, endometrium, myometrium, cervix uteri and portio vaginalis tissues were measured. The results demonstrated good transfer of the drug into various internal genital organs. 2. In clinical studies, CZON was given to 5 cases with various infections such as pyometra, acute vulvitis, pelvic peritonitis, pyelonephritis and puerperal intrauterine infection. Clinical efficacies were evaluated as excellent in 2 cases, and good in 3 cases. The efficacy rate was 100%. No side effects were observed in any cases. In laboratory tests, transient elevations of GOT, GPT and gamma-GTP were observed in 1 case. Therefore, it is concluded that CZON is a useful drug for various types of infections in the field of obstetrics and gynecology.

Adult↗
PubMed1985

The role of peripheral blood T and B lymphocytes in mitogen responses during human pregnancy.

Studies on the role of T and B lymphocytes of pregnant and post-partum women were performed in a pokeweed mitogen (PWM) stimulated culture system. The responses were assessed by immunofluorescent staining for intracytoplasmic immunoglobulins and solid-phase radioimmunoassay for Ig secretion into culture supernatants. As compared with non-pregnant control subjects, a slight decrease of helper T cell function and accelerated suppressor activity of T cells in pregnant and post-partum women in B cell differentiation promoted by PWM were demonstrated. Conversely, B lymphocytes in pregnant and post-partum women were hyperreactive in the presence of T lymphocytes from non-pregnant control subjects in the mitogen stimulated culture system.

Antibodies, Monoclonal↗
PubMed1985

[Fundamental and clinical studies on aztreonam in the field of obstetrics and gynecology].

The following results were obtained through the fundamental and clinical studies of aztreonam (AZT), a new monobactam antibiotic, in obstetrics and gynecology. Satisfactory tissue penetration was not recognized in 3-5 hours after intravenous injection of 1 g. However, the concentration was more than MIC for the majority of aerobic Gram-negative bacteria in intravenous drip infusion of AZT 1 g and in intravenous injection and intravenous drip infusion of 2 g. There was no difference of serum concentration of AZT between uterine arterial blood and cubital venous blood. AZT was administered by intravenous drip infusion to 2 cases of puerperal endometritis, 2 cases (the same patient) of vaginal wall abscess, 1 case of postoperative lymphocele infection and 1 case of infected ovarian cyst suspected, and it was effective for all of them. Neither subjective/objective side effects nor abnormal laboratory findings were noted in any case.

Adult↗